MILLBRAE, Calif., Aug.  18, 2026  (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (&#34;Eikon&#34;), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address

EIKN

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Eikon to host KOL event on PARP inhibitors with MD Anderson expert

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>MILLBRAE, Calif., Aug.  18, 2026  (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (&amp;#34;Eikon&amp;#34;), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Eikon announced its Chairman and CEO will participate in a Cantor Fitzgerald–hosted KOL event on Aug 20, featuring MD Anderson’s Dr. Timothy Yap to discuss PARP inhibition across several cancers. The discussion could provide clinical context and external validation for Eikon&#039;s PARP strategy, though no new data or milestones are disclosed at this time.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Eikon CEO to speak at KOL event Aug 20; PARP landscape discussed.</li><li>Dr. Yap advisor to Eikon; conflict disclosed to UT MD Anderson.</li><li>Event hosted by Cantor Fitzgerald; webcast available for 30 days.</li><li>Focus: PARP inhibitors across breast, ovarian, prostate, pancreatic cancers.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Eikon Therapeutics, Inc. (EIKN)</strong>: Chairman/CEO to participate in KOL event; potential validation for PARP strategy; no data readout.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Category: Industry News. The piece reports on a strategic, non-data event intended to bolster visibility and credibility around EIKN&#039;s PARP program; it could influence sentiment but not immediate fundamentals.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>KOL event on Aug 20 may trigger short-term sentiment movement for EIKN.</li><li>Dr. Yap&#039;s PARP expertise adds credibility to Eikon&#039;s strategy.</li><li>No new clinical data or readouts announced at this event.</li><li>Archived webcast available for 30 days post-event.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Event date/time: Aug 20, 2026 at 9:00 AM ET.</li><li>Host: Cantor Fitzgerald.</li><li>Dr. Timothy A. Yap affiliated with MD Anderson; advisor to Eikon; compensation disclosed to Conflict of Interest Committee.</li><li>Topic: PARP inhibitors in breast, ovarian, prostate, and pancreatic cancer.</li><li>Press release date: Aug 18, 2026; webcast replay available for 30 days.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term neutral-to-bullish tilt if the PARP discussion validates Eikon&#039;s approach through 2H 2026.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>MILLBRAE, Calif., Aug.  18, 2026  (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EIKN">EIKN</a>) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p>  <p>Dr. Timothy A. Yap currently serves as Vice President and Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, and is a Professor in the Department for Investigational Cancer Therapeutics (Phase I Program) and in the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is and/or has been Principal Investigator for multiple clinical trials and translational studies evaluating novel strategies for targeting the DNA damage response in cancer and is an expert in the use of PARP inhibitors in oncology. Dr. Yap receives compensation as an advisor to Eikon, and this financial relationship has been disclosed to UT MD Anderson’s Conflict of Interest Committee in accordance with its institutional policy. Dr. Yap will discuss the current therapeutic landscape of PARP inhibition in breast, ovarian, prostate and pancreatic cancer, including usage of approved agents, therapeutic outcomes and limitations of currently available agents targeting PARP and parylation in oncology.</p>  <p>The event will be hosted by Imogen Mansfield at Cantor Fitzgerald. To access the archived webcast, please visit http://investors.eikontx.com/news-events/events. A replay will be available on the Eikon website for 30 days following the event.</p>  <p><strong>About Eikon Therapeutics</strong><br></br>Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=tHnwL-ZEV3wsfClAWd_2pZOpfj98v-pKGEV_ZaLXmIfGlLfvdRaywn2WYQIgSEoZmH5jSk901dkifENgpBKEIfsoCId_0QsOEBqI-tDXq6A=" rel="nofollow" target="_blank">www.eikontx.com</a>.</p>  <p><strong>Forward-Looking/Safe Harbor Statements</strong><br></br>This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.</p>  <p>These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission ("SEC") on August 13, 2026, and in other public filings with the SEC in the future.</p>  <p>As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.</p>  <p><strong>Contacts:</strong></p>  <p><strong>Investors</strong><br></br>Alfred "Freddie" Bowie, Ph.D., CFO<br></br><a href="https://www.globenewswire.com/Tracker?data=4rONL1JS27PAl3pD1oVQQX-iwXJCzuOxa6UEpi2LMO98aIr-eo0dBkJN-Q5SfFVQfuTB-SVgWUmdEK89aVpTkQ==" rel="nofollow" target="_blank">ir@eikontx.com</a></p>  <p><strong>Media</strong><br></br>Colin Sanford<br></br><a href="https://www.globenewswire.com/Tracker?data=260dwEP97y1r98ADFmj2ZpHlJiX26eUCISsMwkyuEs2TkXI_w9G054fBGgK6OttKZ_IHRM1ZPvS4LiVQ4hUdCf6KcxGT_u3BE80wGVFplKo=" rel="nofollow" target="_blank">colin@bioscribe.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgxMjMxNiM3NzgyNjM3IzIzMDgwOTM="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTkyM2RmMGItMGIxMS00NjJkLTlkYmQtNjFkODc3MGU4NzQ1LTEzMTk2NDMtMjAyNi0wOC0xOC1lbg==/tiny/Eikon-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9"><img src="https://ml.globenewswire.com/media/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9/small/eikon-logo-jpg.jpg" border="0" width="150" height="97" alt="Primary Logo"></img></a></p>

Eikon announced its Chairman and CEO will participate in a Cantor Fitzgerald–hosted KOL event on Aug 20, featuring MD Anderson’s Dr. Timothy Yap to discuss PARP inhibition across several cancers. The discussion could provide clinical context and external validation for Eikon's PARP strategy, though no new data or milestones are disclosed at this time.

News insight

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

AI summary

Sentiment rationale

Key facts

Industry News